Helping mothers and babies, from conception to birth
At Ferring, we are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. Over one third of our research and development investment goes towards finding innovative treatments in reproductive medicine and maternal health. We are also passionate about making a difference to people’s health and quality of life through our work in gastroenterology and orthopaedics.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With over 6,000 employees in 56 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics. Ferring has been developing treatments for mothers and babies for over 50 years.
Ferring Pharmaceuticals Supports the Proclamation of November as Clostridioides difficile Infection Awareness Month in New Jersey and Minnesota-
In conjunction with C. Diff Infection Awareness Month, Ferring Pharmaceuticals launches new educational website Parsippany, New Jersey – November 11, 2021 – Ferring Pharmaceuticals and Rebiotix Inc...
Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021-
New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including those with comorbidities previously exclud...
Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C.Difficile Infection and IBD at ACG 2021-
Parsippany, NJ – October 18, 2021 – Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College o...